A method for manufacturing carboxylic acid that includes the following steps is provided. First, subjecting an aqueous mixture, including carboxylic acid and at least 5 wt. % dissolved magnesium chloride, to a forward extraction step using a first organic liquid, including an organic solvent, the organic solvent being selected from the group of C5+ ketones, thereby obtaining an organic carboxylic acid solution and an aqueous waste liquid including magnesium chloride. Second, subjecting the organic carboxylic acid solution to a back extraction step wherein the carboxylic acid is extracted from the organic carboxylic acid solution into an aqueous liquid, thereby obtaining an aqueous carboxylic acid solution and a second organic liquid. Third, subjecting the aqueous waste liquid including magnesium chloride derived from the forward extraction to a thermal decomposition step at a temperature of at least 300° C., thereby decomposing the magnesium chloride to magnesium oxide and HCl.

Efficient production of a carboxylic acid is provided by a method of producing a carboxylic acid, which includes the following steps (A) and (B): (A) filtering a carboxylic acid-containing fermentation broth by passing said fermentation broth through a nanofiltration membrane, to obtain a carboxylic acid-containing filtrate from the permeate side of the membrane; and (B) extracting the carboxylic acid from the carboxylic acid-containing filtrate obtained in the step (A) using an extraction solvent which undergoes phase separation with the filtrate, and collecting a carboxylic acid extract phase-separated from the aqueous phase.

Efficient production of a carboxylic acid is provided by a method of producing a carboxylic acid, which includes the following steps (A) and (B): (A) filtering a carboxylic acid-containing fermentation broth by passing said fermentation broth through a nanofiltration membrane, to obtain a carboxylic acid-containing filtrate from the permeate side of the membrane; and (B) extracting the carboxylic acid from the carboxylic acid-containing filtrate obtained in the step (A) using an extraction solvent which undergoes phase separation with the filtrate, and collecting a carboxylic acid extract phase-separated from the aqueous phase.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

A method for separating trans isomer crocetin from cis isomer crocetin is provided. The method comprises crystallizing all-trans crocetin with calcium ions first by using different binding capabilities between cis and trans isomeric crocetin to calcium ions and acidifying the all-trans crocetin to obtain 13-cis crocetin.

A method for separating trans isomer crocetin from cis isomer crocetin is provided. The method comprises crystallizing all-trans crocetin with calcium ions first by using different binding capabilities between cis and trans isomeric crocetin to calcium ions and acidifying the all-trans crocetin to obtain 13-cis crocetin.

Provided herein are reactor systems and processes for producing organic acids directly from beta-lactones. Such reactor systems and processes involve the use of a heterogeneous catalyst, such as a zeolite at vapor phase conditions. The reactor systems and processes may use a fixed bed, moving bed or fluidized contacting zone as reactor configurations.

Provided herein are reactor systems and processes for producing organic acids directly from beta-lactones. Such reactor systems and processes involve the use of a heterogeneous catalyst, such as a zeolite at vapor phase conditions. The reactor systems and processes may use a fixed bed, moving bed or fluidized contacting zone as reactor configurations.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.